Edwin M. Posadas, MD, FACP | Authors

Articles

A Phase Ib Study of Abiraterone Plus Docetaxel for mCRPC

September 11, 2014

Edwin M. Posadas, MD, FACP, discusses the results of a phase Ib study that looked at abiraterone and docetaxel for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Analysis of a Phase II Study of Cabozantinib in mCRPC

July 15, 2014

Edwin M. Posadas, MD, FACP, medical director, Urologic Oncology Program, Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute, discusses a translational phase II study of cabozantinib in men with metastatic castration-resistant prostate cancer (mCRPC) with visceral metastases with characterization of circulating tumor cells and large oncosomes.